LY2127399 + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Relapsing-Remitting Multiple Sclerosis

Conditions

Relapsing-Remitting Multiple Sclerosis

Trial Timeline

Apr 1, 2009 → Jun 1, 2012

NCT ID

NCT00882999

About LY2127399 + Placebo

LY2127399 + Placebo is a phase 2 stage product being developed by Eli Lilly for Relapsing-Remitting Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00882999. Target conditions include Relapsing-Remitting Multiple Sclerosis.

What happened to similar drugs?

20 of 20 similar drugs in Relapsing-Remitting Multiple Sclerosis were approved

Approved (20) Terminated (4) Active (0)

✅Rebif® + Rebif®MerckApproved

✅Interferon beta-1a (Rebif)MerckApproved

✅Cladribine 10 mg oral tabletMerckApproved

✅Ofatumumab + Disease modifying treatment (DMT)NovartisApproved

✅fingolimodNovartisApproved

✅FingolimodNovartisApproved

✅fingolimodNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01488708	Phase 3	Terminated	Jan 1, 2012	Oct 1, 2015	Systemic Lupus Erythematosus
NCT01202760	Phase 3	Completed	Jan 1, 2011	Jul 1, 2013	Rheumatoid Arthritis
NCT00882999	Phase 2	Completed	Apr 1, 2009	Jun 1, 2012	Relapsing-Remitting Multiple Sclerosis
NCT00785928	Phase 2	Completed	Oct 1, 2008	Dec 1, 2010	Rheumatoid Arthritis
NCT00689728	Phase 2	Completed	Jun 1, 2008	May 1, 2010	Arthritis, Rheumatoid
NCT00308282	Phase 2	Completed	Mar 28, 2006	Oct 18, 2007	Arthritis, Rheumatoid

Competing Products

20 competing products in Relapsing-Remitting Multiple Sclerosis

See all competitors

Product	Company	Stage	Hype Score
CT-P53 + US-Ocrevus + EU-Ocrevus	Celltrion	Phase 3	47
BIIB019 (Daclizumab High Yield Process) + Placebo	AbbVie	Phase 2	35
Daclizumab	AbbVie	Phase 3	32
BIIB019 (Daclizumab High Yield Process) + Placebo	AbbVie	Phase 2	35
BIIB019 (Daclizumab) + trivalent seasonal influenza vaccine	AbbVie	Phase 2	35
BIIB019 (Daclizumab)	AbbVie	Phase 3	32
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process Placebo	AbbVie	Phase 3	40
Rebif (Interferon beta-1a)	Merck	Pre-clinical	26
Interferon beta-1a	Merck	Pre-clinical	26
Rebif® + Avonex®	Merck	Phase 3	40
Rebif® + Rebif®	Merck	Approved	43
VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) alone	Merck	Phase 2	35
Placebo + IFN beta-1a + Methylprednisolone	Merck	Phase 2	27
Interferon beta-1a (Rebif)	Merck	Approved	43
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched Placebo	Merck	Phase 3	32
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched Placebo	Merck	Phase 3	32
Interferon beta 1a	Merck	Pre-clinical	26
Cladribine 10 mg oral tablet	Merck	Approved	39
Evobrutinib + Evobrutinib + Evobrutinib + Placebo + Tecfidera	Merck	Phase 2	27
Minocycline + Placebo	Merck	Phase 2	27